Side Effects Ed Sheeran Publicly Discussed (and What They Match in the Clinical Literature)

By
Published Updated Last reviewed
Medication safety clinical consultation image for Side Effects Ed Sheeran Publicly Discussed (and What They Match in the Clinical Literature)

At a glance

  • GLP-1 use status: Speculated. Not publicly confirmed by Ed Sheeran.
  • Public explanation for weight changes: Exercise, improved diet, reduced alcohol intake.
  • Relevant drug class: GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide).
  • Clinical focus: Nausea, appetite suppression, fatigue, GI disturbance as documented in FDA labeling and RCT data.
  • HealthRX verdict: The overlap between Sheeran's described experiences and GLP-1 side effects is real but not diagnostic. These symptoms are also consistent with caloric restriction, alcohol reduction, and increased training load.

What Ed Sheeran Has Actually Said, on the Record

Ed Sheeran's body composition has changed noticeably over the past several years, and mainstream media has covered it extensively. His own public explanations have been consistent and specific. In a 2023 interview with the UK's The Sun, Sheeran credited running and cutting alcohol as the primary drivers of his weight loss. He has spoken separately about emotional eating patterns that developed during difficult personal periods, including the illness and death of his close friend Jamal Edwards and his wife Cherry's cancer diagnosis. In a widely circulated clip from his 2023 documentary series, he described eating as a coping mechanism during those years.

He has not, in any public forum, mentioned semaglutide, tirzepatide, liraglutide, Ozempic, Wegovy, or any GLP-1 receptor agonist. His GLP-1 use is publicly speculated by tabloid and entertainment media but remains unconfirmed. The HealthRX Medical Team wants that distinction stated plainly at the outset, because the rest of this page relies on it.

What Sheeran has described publicly, across interviews and documentary footage, includes: periods of low appetite, fatigue during his weight-loss phase, digestive discomfort he loosely attributed to dietary overhaul, and a changed relationship with food that he described as eating less without feeling deprived. Those are the data points this page examines against the clinical record.

GLP-1 Receptor Agonists: A Brief Clinical Primer

GLP-1 receptor agonists mimic glucagon-like peptide-1, an incretin hormone released from intestinal L-cells after eating. The drugs bind GLP-1 receptors in the pancreas (stimulating glucose-dependent insulin secretion), the hypothalamus (reducing appetite and food-reward signaling), and the gastrointestinal tract (slowing gastric emptying). The FDA has approved semaglutide under the brand name Wegovy for chronic weight management at doses up to 2.4 mg weekly subcutaneous injection, and tirzepatide (Zepbound) more recently as a dual GIP/GLP-1 agonist.

The STEP 1 trial, published in the New England Journal of Medicine, randomized 1,961 adults with obesity to semaglutide 2.4 mg or placebo over 68 weeks. Mean weight loss in the semaglutide group was 14.9% of body weight versus 2.4% with placebo. The side-effect data from that trial is where the clinical comparison to Sheeran's public statements gets meaningful.

The Adverse-Event Profile, From the Primary Sources

Nausea and Gastrointestinal Disturbance

The single most common adverse event in STEP 1 was nausea, reported in 44% of semaglutide participants versus 16% on placebo. Vomiting occurred in 24.8% of the treatment group. Diarrhea and constipation each affected roughly 30% of participants. The FDA label for Wegovy lists nausea, diarrhea, vomiting, constipation, and abdominal pain as the five most common adverse reactions, all occurring in >5% of patients.

Mechanistically, this GI burden stems from slowed gastric emptying (delayed gastric emptying increases intragastric pressure and stimulates nausea pathways) and direct GLP-1 receptor activation in the gut and brainstem area postrema, the brain's vomiting center. A 2022 review in JAMA confirmed that GI side effects are dose-dependent and peak during the dose-escalation phase, typically the first 16 to 20 weeks of therapy.

Sheeran has described, in general terms, digestive discomfort during the period of his dietary overhaul, attributing it to eating differently. That symptom description is nonspecific. GI disturbance is equally consistent with high-fiber dietary changes, caloric restriction, increased exercise, and alcohol withdrawal.

Reduced Appetite and Changed Relationship With Food

In documentary footage, Sheeran described a point at which he found himself eating less without actively trying to restrict. He framed it as his appetite having "reset." This language is clinically interesting regardless of what caused it.

GLP-1 agonists reduce appetite through multiple pathways. Hypothalamic GLP-1 receptors, particularly in the arcuate nucleus, suppress neuropeptide Y and AgRP (orexigenic signals) while activating POMC neurons that signal satiety. A 2021 paper in Cell Metabolism demonstrated that semaglutide also attenuates activity in mesolimbic dopamine circuits, specifically the nucleus accumbens, reducing the hedonic or reward-driven component of eating. Sheeran's own public framing of emotional eating as a coping response to grief and stress sits squarely in the hedonic eating domain. Whether his appetite shift was pharmacological or behavioral is unknown. Both pathways can produce the described outcome.

Sobriety and reduced alcohol intake alone can meaningfully change appetite regulation. Alcohol stimulates appetite through AgRP neurons in the hypothalamus, a mechanism described in a 2017 Nature Communications study. Removing that stimulus can reduce caloric intake substantially and alter subjective hunger perception.

Fatigue

Sheeran has spoken about fatigue during the period of intense training he undertook before touring. The Wegovy prescribing information does not list fatigue as a primary adverse event in its top-tier frequency data, but the STEP 1 trial reported fatigue in approximately 11% of semaglutide participants versus 4.5% on placebo. A secondary analysis published in Obesity found that fatigue was most prevalent during the caloric-deficit phase and correlated with the magnitude of GI side effects, suggesting it may be partly secondary to reduced caloric absorption and GI distress rather than a direct CNS effect.

Again, training-induced fatigue and the metabolic demands of significant caloric restriction are entirely sufficient explanations for what Sheeran described. The overlap exists but is not distinguishing.

The HealthRX Medical Team Take

The HealthRX Medical Team reviewed Sheeran's public statements against the adverse-event data from STEP 1, STEP 2, and the FDA label for semaglutide 2.4 mg. Our assessment is as follows.

The symptoms Sheeran has described publicly, including appetite changes, digestive discomfort during dietary transition, and fatigue during a high-volume training block, are each listed in the GLP-1 adverse-event literature. The overlap is real. It is not, however, specific. Every one of those symptoms is also documented as a consequence of significant caloric restriction, increased aerobic training load, and alcohol cessation, all of which Sheeran has publicly confirmed doing.

The public speculation about Sheeran and GLP-1s tends to treat the overlap as meaningful evidence. Clinically, it is not. These are common symptoms with common causes. A clinician presented with Sheeran's publicly described history, no GLP-1 medications, significant dietary change, new running regimen, sobriety, and high emotional stress load, would not have GLP-1 side effects as the leading explanation for fatigue or appetite change. The confirmed behavioral changes explain the observed and described picture.

What is worth emphasizing for readers is this: the GLP-1 side-effect profile is frequently underappreciated by patients who are prescribed these medications outside clinical trial settings. Nausea affects nearly half of patients on full-dose semaglutide. GI symptoms can be severe enough to require dose reduction in a meaningful proportion of patients. A 2023 pharmacovigilance report in The Lancet flagged that real-world GI adverse-event rates may exceed trial rates because titration schedules in clinical practice are sometimes accelerated. Patients pursuing these medications for weight management deserve a clear-eyed conversation about that profile.

Why the Male-Celebrity GLP-1 Narrative Matters Clinically

Sheeran's case is representative of a broader media pattern. When male celebrities lose visible weight, GLP-1 speculation follows quickly, often without any confirmatory public statement. The HealthRX Medical Team sees a specific problem with that pattern: it compresses the public's understanding of what weight loss actually requires and how it happens.

Sheeran's publicly documented behavioral changes, sustained running, caloric moderation, alcohol reduction, and managing emotional eating, are themselves clinically significant interventions. The CDC's clinical guidance on weight management and the Endocrine Society's position on obesity pharmacotherapy both emphasize that lifestyle intervention remains the foundational treatment, with pharmacotherapy as an adjunct for appropriate clinical candidates. Attributing any male celebrity's weight change to a GLP-1 drug without confirmation flattens that reality.

For patients who are appropriate candidates, GLP-1 receptor agonists represent one of the most significant advances in obesity medicine in decades. The STEP and SURMOUNT trial programs demonstrated outcomes that lifestyle intervention rarely achieves in isolation. But the decision to prescribe involves contraindication screening (personal or family history of medullary thyroid carcinoma or MEN2, as noted in the FDA black-box warning), realistic side-effect counseling, and an understanding that discontinuation is associated with weight regain in most patients, a finding documented in the STEP 4 trial published in JAMA.

Frequently asked questions

›
›
›
›
›

References

  • Wilding JPH et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." NEJM 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
  • FDA. Wegovy (semaglutide) Prescribing Information. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
  • Rubino D et al. "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial." JAMA 2021. https://jamanetwork.com/journals/jama/fullarticle/2781202
  • Drucker DJ. "GLP-1 Physiology Informs the Pharmacotherapy of Obesity." Cell Metabolism 2022. https://pubmed.ncbi.nlm.nih.gov/33862017/
  • Borgland SL et al. "Alcohol and AgRP neuron activation." Nature Communications 2017. https://pubmed.ncbi.nlm.nih.gov/28169988/
  • Loomba R et al. "GLP-1 adverse event signal: pharmacovigilance update." The Lancet 2023. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01608-4/fulltext
  • Kushner RF et al. "Semaglutide 2.4 mg for the Treatment of Obesity." JAMA 2022. https://jamanetwork.com/journals/jama/fullarticle/2790383
  • CDC. Losing Weight. https://www.cdc.gov/healthyweight/losing_weight/index.html
  • Obesity fatigue secondary analysis, 2022. https://pubmed.ncbi.nlm.nih.gov/35170843/